Holen Sie sich die Stockscreener-App
432.83
1.48%
-6.51
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt MDGL?
Forum
Prognose
Aktiensplit
Madrigal Pharmaceuticals Inc Aktie (MDGL) Neueste Nachrichten
Teachers Retirement System of The State of Kentucky Invests $1.32 Million in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
20 new Madrigal staff get stock options and 6,882 RSUs at $432 - Stock Titan
Aug Shorts: Will UnitedHealth Group Incorporated stock go up in YEARQuarterly Performance Summary & High Accuracy Investment Entry Signals - baoquankhu1.vn
Risk Check: Can Madrigal Pharmaceuticals Inc weather a recessionWeekly Stock Analysis & Safe Entry Momentum Stock Tips - baoquankhu1.vn
Segall Bryant & Hamill LLC Invests $10.32 Million in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
A Look At Madrigal Pharmaceuticals (MDGL) Valuation After Recent Share Price Weakness - simplywall.st
Madrigal Pharmaceuticals: How Noninvasive Data Is Powering a Smarter Clinical Strategy! - Smartkarma
Madrigal Pharmaceuticals, Inc. $MDGL Shares Sold by TD Asset Management Inc - MarketBeat
Madrigal Revenue Beats Highlight Rezdiffra Momentum And Investor Trade Offs - simplywall.st
MDGL: Rezdiffra's growth accelerates with a broad pipeline and strong 2026 financial outlook - TradingView
Intech Investment Management LLC Lowers Holdings in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Madrigal Pharmaceuticals (MDGL) Reports Record 2025 Revenue Driven by Rezdiffra Success - Finviz
Madrigal Pharmaceuticals EVP Dier sells $505k in shares By Investing.com - Investing.com Canada
Madrigal Pharmaceuticals (NASDAQ:MDGL) CFO Mardi Dier Sells 1,183 Shares - MarketBeat
Madrigal Pharmaceuticals (MDGL) director sale notice: 1,183 shares after RSU vest - Stock Titan
MADRIGAL PHARMACEUTICALS EVP and CFO Sells Shares to Cover Tax Obligations - TradingView
Madrigal (MDGL) CFO has shares sold automatically for tax withholding - Stock Titan
Madrigal Pharmaceuticals, Inc. (MDGL) Stock Analysis: Exploring a 54% Upside Potential in the Biotech Sector - DirectorsTalk Interviews
Rafferty Asset Management LLC Lowers Stock Holdings in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
JPMorgan Chase & Co. Reduces Stake in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
William Blair Investment Management LLC Has $188.88 Million Stock Position in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Artisan Partners Limited Partnership Acquires 4,683 Shares of Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Madrigal Q4 earnings miss, MASH drug sales drive top line, stock down - MSN
MDGL SEC FilingsMadrigal Pharmac 10-K, 10-Q, 8-K Forms - Stock Titan
Fox Run Management L.L.C. Takes $1.06 Million Position in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Why Madrigal Pharmaceuticals (MDGL) Is Down 9.7% After Rezdiffra’s Near US$1 Billion Debut Year - Yahoo Finance
Exit Recap: Will Madrigal Pharmaceuticals Inc outperform during market ralliesEarnings Summary Report & Weekly Setup with High ROI Potential - baoquankhu1.vn
Madrigal: The Easiest Money May Have Been Made (NASDAQ:MDGL) - Seeking Alpha
Director exercises 2,500 Madrigal (MDGL) options at $7.36 - Stock Titan
Madrigal Pharmaceuticals Reports 2025 Financial Results - MyChesCo
Madrigal Pharmaceuticals to Participate in the TD Cowen 46th Annual Health Care Conference - The Manila Times
Madrigal to webcast TD Cowen health conference talk Mar. 3 - Stock Titan
Madrigal Grants Inducement Awards to Five Employees - MyChesCo
Madrigal (MDGL) Q4 2025 Earnings Call Transcript - The Globe and Mail
A Look At Madrigal Pharmaceuticals (MDGL) Valuation After Rezdiffra’s First Full Year Near US$1b In Sales - simplywall.st
Madrigal Pharmaceuticals, Inc. (MDGL): Investor Outlook Reveals 53% Potential Upside In Biotechnology - DirectorsTalk Interviews
Vanguard Group Inc. Sells 65,227 Shares of Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Madrigal’s Rezdiffra Breakthrough Spurs MASH Pipeline Growth And Valuation Debate - Yahoo Finance
MASH Drugs Market to hit US$ 929.05 Million by 2033 | North America - openPR.com
Madrigal Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (5 Ratings) - Benzinga
Madrigal Q4 Earnings Miss, MASH Drug Sales Drive Top Line, Stock Down - Bitget
Is now the right time to enter Madrigal Pharmaceuticals Inc.July 2025 Opening Moves & Safe Entry Momentum Tips - mfd.ru
MDGL: B of A Securities Maintains Neutral Rating, Lowers Price T - GuruFocus
Bank of America Issues Pessimistic Forecast for Madrigal Pharmaceuticals (NASDAQ:MDGL) Stock Price - MarketBeat
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Q4 2025 Earnings Call Transcript - Insider Monkey
Fiera Capital Corp Lowers Stock Holdings in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Madrigal sees a stock sell-off; ex-Novartis exec heads to Daiichi - Yahoo Finance
Madrigal inks licensing deal with China’s Suzhou Ribo for MASH drugs - MSN
Decoding Madrigal Pharmaceuticals Inc (MDGL): A Strategic SWOT I - GuruFocus
Madrigal Pharma earnings missed by $1.97, revenue topped estimates - Investing.com Canada
Madrigal Eyes MASH Future As Rezdiffra Nears Blockbuster Revenue - Citeline News & Insights
Earnings call transcript: Madrigal Pharmaceuticals Q4 2025 misses EPS, stock dips - Investing.com India
Madrigal Pharmaceuticals Inc (MDGL) Q4 2025 Earnings Call Highlights: Record Sales and ... By GuruFocus - Investing.com Canada
Madrigal Pharmaceuticals Inc (MDGL) Q4 2025 Earnings Call Highli - GuruFocus
Madrigal Pharmaceuticals (NASDAQ:MDGL) Posts Quarterly Earnings Results, Misses Estimates By $2.61 EPS - MarketBeat
Madrigal Pharmaceuticals, Inc. reports strong Rezdiffra sales growth in Q4 2025; first full year of launch approaches $1 billion in net sales - AlphaStreet News
Madrigal Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Madrigal Pharmaceuticals (MDGL) Reports Strong Q4 2025 Performan - GuruFocus
Madrigal Pharmaceuticals Q4 2025 Earnings Call Transcript - MarketBeat
Madrigal Pharmaceuticals (NASDAQ:MDGL) Shares Gap Down After Earnings Miss - MarketBeat
Madrigal Pharmaceuticals Q4 Earnings Call Highlights - MarketBeat
Madrigal Pharmaceuticals Stock Drops 11% Despite Reporting Narrower Loss In Q4 - Nasdaq
Sector Update: Health Care Stocks Flat to Lower Pre-Bell Thursday - marketscreener.com
1.24%
2.79%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):